Browse the evidence

If all eligible individuals received medically tailored meals (MTMs), an estimated 1,594,000 hospitalizations could potentially be averted in 1 year.

Healthcare providers should consider the potential benefits of MTMs in reducing hospitalizations for eligible patients.

GLP1-RA treatment is associated with improvements in restrained eating and emotional eating behavior compared with placebo.

GLP1-RAs may help improve eating behaviors in this population.

Power training (PT) was associated with an improvement in physical function compared to traditional strength training in older adults.

Practitioners may consider incorporating power training into exercise programs for older adults to enhance physical function.

Power training was associated with an improvement in self-reported physical function compared to traditional strength training.

Incorporating power training may enhance older adults' self-perception of physical function.

Mean percentage weight change at 1 year was -5.1% with semaglutide compared to -2.2% with liraglutide (P < .001).

Semaglutide may be more effective than liraglutide for weight loss in clinical practice.

Obesity as a treatment indication was associated with a higher likelihood of achieving a 10% or greater weight reduction (AOR, 2.46).

Patients with obesity may experience better weight loss outcomes compared to those with type 2 diabetes.

Persistent medication coverage was associated with a higher likelihood of achieving a 10% or greater weight reduction (AOR, 3.36).

Ensuring patients maintain their medication regimen may significantly improve weight loss outcomes.

Weight change at 6 months was -4.31% for the standardized group and -3.26% for the personalized group.

Both diet approaches resulted in weight loss, but the standardized low-fat diet was more effective.

Tirzepatide facilitated an average 18.5% weight loss (>46 pounds) in overweight and obese patients with type 1 diabetes at 1 year.

Practitioners may consider tirzepatide as an effective option for weight management in this patient population.

Regular exercise promotes, maintains, and restores healthy functioning of nearly every physiological system of the human body.

Practitioners should encourage regular exercise as a key component of health maintenance.

Adequate dietary sources or supplements of specific nutrients are necessary for vegan diets.

Health professionals should ensure that vegan patients receive adequate nutrients through diet or supplements.

In the obesity cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -12.3% to -16.2%, compared to -2.5% with placebo.

Maridebart cafraglutide may be an effective treatment option for weight loss in individuals with obesity.

In the obesity-diabetes cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -8.4% to -12.3%, compared to -1.7% with placebo.

Maridebart cafraglutide may also be effective for weight loss in individuals with obesity and type 2 diabetes.

The Mediterranean Diet may be of greater interest for the management of T2DM.

Consider recommending the Mediterranean Diet as a potential strategy for managing T2DM.

The recommended dietary prescription for the Mediterranean Diet includes 40-50% carbohydrates, 15-25% proteins, and 25-35% fats.

Use these macronutrient guidelines when advising patients on the Mediterranean Diet for T2DM management.

The ACSM supports the inclusion of physical activity in medical treatments for excess weight and adiposity.

Practitioners should incorporate physical activity into treatment plans for patients with excess weight.

For weight loss and prevention of weight gain, physical activity should be progressed to at least 150 min·wk-1 of moderate-intensity.

Encourage clients to engage in at least 150 minutes of moderate-intensity physical activity weekly for effective weight management.

The low-carbohydrate diet intervention group had a significantly greater 6-month reduction in HbA1c of -0.23% compared to the usual diet group.

A low-carbohydrate diet may be effective in reducing HbA1c levels in individuals with prediabetes or untreated diabetes.

The low-carbohydrate diet intervention group experienced a significant reduction in fasting plasma glucose of -10.3 mg/dL.

Implementing a low-carbohydrate diet may help lower fasting plasma glucose levels in individuals with prediabetes or untreated diabetes.

The low-carbohydrate diet intervention group had a significant reduction in body weight of -5.9 kg.

A low-carbohydrate diet may contribute to significant weight loss in individuals with prediabetes or untreated diabetes.

GLP-1 receptor agonists safely cause weight loss and have potential weight-independent anti-inflammatory effects.

Practitioners may consider GLP-1 receptor agonists as a treatment option for weight loss and inflammation in these patient populations.

A diet that recapitulated key characteristics of non-industrialized dietary patterns improved gut microbiome interactions and provided cardiometabolic benefits.

Practitioners may consider recommending dietary patterns that mimic non-industrialized diets to improve gut health and cardiometabolic outcomes.

Weight loss and fat mass loss through lifestyle and pharmacologic interventions improve metabolic and inflammatory markers, suggesting a link to decreased breast cancer risk.

Practitioners should encourage weight loss and fat mass reduction as strategies to lower breast cancer risk.

bMVPA performed in the afternoon is associated with a greater reduction in HbA1c compared to inactive individuals, with a reduction of -0.22%.

Practitioners may consider recommending afternoon physical activity to improve glycemic control in patients with type 2 diabetes.